Bevacizumab biosimilar (Genor Biopharma)

重组抗血管内皮生长因子人源化单抗（嘉和生物）

Report date: 2022/03/14 18:12:49

Base Information

Drug NameBevacizumab biosimilar (Genor Biopharma)

Drug Alias NameRecombinant humanized anti-VEGF monoclonal antibody (Genor Biopharma)贝伐赛珠单抗生物仿制药（嘉和生物）贝伐单抗生物仿制药（嘉和生物）贝伐人源化单抗生物仿制药（嘉和生物）贝伐珠单抗生物仿制药（嘉和生物） +[6]

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungBrain NeoplasmsGlioma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaPhase 3 Clinical

Originator CompaniesGenor Biopharma Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesGenor Biopharma Co Ltd

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell LungBrain Neoplasms

Inactive IndicationsGlioma

Other Information

ATC CodeL01XC07